Skip to the stories
Wednesday, 18 November 2026
Saved

Next edition

16:03

Headlines

Stocks & Bonds

Vir Biotechnology Reports Positive Results in Clinical Trials for Hepatitis Delta Treatment

Vir Biotechnology announced that its experimental combination treatment for chronic hepatitis delta met its primary phase 3 trial goal and showed sustained suppression in phase 2.

FTMQ Business, written by our newsroom0 views

Share
Picture: Seeking Alpha Markets

Vir Biotechnology announced on Sunday that its experimental combination treatment for chronic hepatitis delta met its primary goal in a phase 3 clinical trial. Seeking Alpha Markets and Seeking Alpha both reported that separate phase 2 results showed sustained suppression of the virus in patients who stopped treatment. [1][4]

Mugglehead Investment Magazine reported that Vir Biotechnology met the phase 3 hepatitis delta endpoint with a 44 percent response rate. Quantisnow also reported that the primary endpoint was met in the pivotal phase 3 trial. Additionally, GuruFocus reported promising phase 2 trial results for chronic hepatitis delta. [3][5][6]

Vir Biotechnology was founded in 2016 and focuses on engineering antibodies to treat viral infections and related conditions. The company maintains a development pipeline targeting chronic hepatitis delta virus and collaborates with partners such as Alnylam Pharmaceuticals, Brii Biosciences Limited, GlaxoSmithKline Biologicals, and the Gates Foundation. [8]

Share

In short

  • Vir Biotechnology announced that its experimental combination treatment for chronic hepatitis delta met its primary endpoint in a phase 3 clinical trial.
  • Mugglehead Investment Magazine reported a 44 percent response rate in the phase 3 trial.
  • Phase 2 clinical trial results showed sustained viral suppression in patients who stopped treatment.

Sources

Every paragraph above points to the numbered items it rests on. Read the originals here.

  1. [1]Vir Biotechnology reports positive hepatitis results, early signs of possible cureSeeking Alpha Markets, 9d ago (the report this story comes from)
  2. [2]Vir Biotechnology, Inc. (VIR) Stock Price, News, Quote & HistoryYahoo! Finance Canada, 9d ago
  3. [3]Vir Biotechnology Announces Primary Endpoint Met in Pivotal Phase 3...Quantisnow, 9d ago
  4. [4]Vir Biotechnology reports positive hepatitis results, early signs of possible cure (VIR:NASDAQ)Seeking Alpha, 9d ago
  5. [5]Vir Biotechnology meets Phase 3 hepatitis delta endpoint with 44% responseMugglehead Investment Magazine, 9d ago
  6. [6]Vir Biotechnology (VIR) Reports Promising Phase 2 Results for ChGuruFocus, 9d ago

Background

  1. [7]List of S&P 600 companies on Wikipedia
  2. [8]Vir Biotechnology on Grokipedia

Our newsroom writes these reports with the help of software, from the 8 sources listed and nothing else, and checks them against those sources. Facts can still be wrong or move on; the originals are the record. Spotted a mistake? Write to daniel@monsterkong.com.

Earlier reports of ours on the same people and subjects.

More in Stocks & Bonds

Get the day in one email

Reports like this one, the top news of the last 24 hours, every morning. Free, one email a day; readers can comment under every report.

By signing up you agree to our terms and privacy policy. Unsubscribe any time.

Comments

Loading

Join the conversation

Comments are open to readers of our daily email: the top news of the last 24 hours, every morning, free. Sign up and the comment box opens.

Already on the list? Enter the same address and we will send a sign-in link.

By signing up you agree to our terms and privacy policy. Unsubscribe any time.